Microwave ablation of hepatocellular carcinoma as first-line treatment: long term outcomes and prognostic factors in 221 patients

Tao Wang¹⁺, Xiao-Jie Lu²⁺, Jia-Chang Chi³, Min Ding¹, Yuan Zhang¹, Xiao-Yin Tang¹, Ping Li¹, Li Zhang³, Xiao-Yu Zhang⁴ & Bo Zhai¹

This retrospective study aimed at evaluating the long-term outcomes and prognostic factors of microwave ablation (MWA) as a first-line treatment for hepatocellular carcinoma (HCC). 221 consecutive patients receiving MWA in our center between October 11, 2010 and December 31, 2013 were enrolled. Technique effectiveness was evaluated one month post-ablation. Initial complete ablation (CA1st) was gained in 201 (90.95%) patients, secondary CA (CA2nd) in 8 (3.62%) patients and the remaining 12 (5.43%) patients suffered from incomplete ablation (IA2nd) after two sessions of MWA. Patients with tumor size > 5 cm were less likely to gain CA1st. Procedure-related complications were recorded and no procedure-related death occurred. 22 (10.4%) complications occurred with 8 (3.8%) being major ones. Tumor characteristics (size, number, location) do not significantly influence complication rates.

After a median follow-up of 41.0 (ranging 25.0–63.5) months, the median RFS and OS was 14.0 months (95% CI: 9.254–18.746) and 41.0 months (95% CI: 33.741–48.259) respectively. Multivariate analysis identified two significant prognosticators (levels of alpha fetal protein [AFP] and gamma-glutamyl transpeptidase [GGT]) of RFS and five significant prognosticators (tumor number, tumor size, AFP, GGT and recurrence type) of OS. In conclusion, MWA provides high technique effectiveness rate and is well tolerated in patients with HCC as a first-line treatment.
Methods and Materials

Patient enrollment. The protocol of this study conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki and was approved by the Institutional Ethics Committee of Renji Hospital (Shanghai, China). The medical records of HCC patients who received MW A in Renji Hospital (Shanghai, China) from October 11, 2010 to December 31, 2013 were retrieved and reviewed. Informed consents from patients to allow the review and analyses of their medical records were obtained. The flowchart of patient enrollment of this study is shown in Fig. 1.

Patients inclusion criteria: (1) HCC patients who received ultrasound-guided percutaneous MW A as an initial anticancer treatment; (2) Total number of tumor lesions ≤ 3; (3) Largest single tumor diameter ≤ 10 cm; (4) For patients with multiple tumors (2 or 3), no more than one lesion > 5 cm; (5) ECOG (Eastern Cooperative Oncology Group) performance status (PST): 0–1; (6) Child-Pugh score A or B; (7) Adequate hematologic (platelet count > 40 × 10^9/L, INR < 2.0) and renal (creatinine > 2.0 mg/dL) functions.

Patients exclusion criteria: (1) Patients who received anticancer treatment before MW A, such as hepatic resection, sorafenib, radiofrequency ablation or transcatheter arterial chemoembolization (TACE); (2) Patients who received laparoscopic MW A or intraoperative MW A rather than percutaneous MW A as initial treatment (for tumors protruding from liver surface; for tumors contacting or adhering to diaphragm or abdominal viscera; or for patients with comorbid diseases needing laparoscopy or laparotomy surgery); (3) Patients with portal vein, hepatic vein or inferior vena cava invasion, extrahepatic metastases, or malignancies of other tissue-of-origin; (4) Patients with signs of decompensated cirrhosis such as clinical hepatic encephalopathy and refractory ascites.

Diagnosis, staging and treatment allocation of HCC. HCC was diagnosed according to the recommendations by the European Association For The Study Of The Liver (EASL)^6. Briefly, for patients without liver cirrhosis, the diagnosis of HCC was confirmed by biopsies assessed by expert hepatopathologists. For patients with cirrhosis, the diagnosis of HCC require typical features (hypervascular in the arterial phase with washout in the portal venous or delayed phases on multidetector CT scan/dynamic contrast-enhanced MRI) on one imaging technique for nodules > 2 cm and on two imaging techniques for those of 1–2 cm. In case of uncertainty or atypical radiological findings, diagnosis was confirmed by biopsy assessed by expert hepatopathologists.

HCC were staged according to the Cancer of the Liver Italian Program (CLIP) stage^13 and Barcelona Clinic Liver Cancer (BCLC) stage^14.

For each patient, treatments were allocated based on patient will and clinicopathological characteristics, which were assessed by the HCC Expert Team in Renji Hospital. This team comprised hepatologists, liver surgeons, interventional radiologists and oncologists.

It should be noted that although a substantial part of patients included in our study were candidates for liver resection or liver transplantation according to mainstream guidelines^5,6, they received MW A rather than surgical
treatments for the following reasons: (1) refusing surgical treatments for psychological/religious reasons; (2) contraindicated to surgical treatments after assessed by our HCC Expert Team (for example, compromised cardio-pulmonary function); (3) unable to receive liver transplantation due to lack of suitable transplant organ or due to economic reasons.

It is also noteworthy that in our institute, the initial treatment options for patients beyond Milan criteria (single tumors \(\leq 5\) cm or 3 nodules \(\leq 3\) cm) included TACE, MWA, RFA, liver resection, liver transplantation and sorafenib (Fig. 1). There were 55 patients in our study, for example, with tumors \(>5\) cm in diameter. These patients received MWA rather than TACE as an initial treatment because the tumors could be clearly delineated under ultrasound and had a high likelihood to be completely ablated by MWA as assessed by our HCC expert team.

### Procedures and technical parameters of percutaneous MWA under ultrasound guidance.

All MWA procedures were performed percutaneously guided by real-time ultrasound (MyLab Twice scanner or HM1498XS1 scanner) using a 3.5 Mhz probe. The selection of local or general anesthesia was based on tumor number, size and location. General anesthesia was performed in patients with tumors \(\geq 3\) cm in diameter, multiple tumors, or tumors adjacent to nerve-rich areas such as abdominal wall or major hepatic vessels. Vital signs were monitored throughout the procedures.

MWA was performed with a 2450 MHZ MTC-3C microwave generator (Vision Medical, Nanjing, China), which has a 25 cm cooled-shaft electrode probe (15-gauge) with a 1.5 cm expandable tip. Power output was set at 80 to 100 watts.

During ablation procedure, complete coverage of the tumor region by hyperechoic under real-time ultrasound was regarded as a measure of complete ablation. In non-risk areas (definition shown below), at least 0.5 cm of the normal hepatic parenchyma surrounding the tumor was ablated as an ablative margin to guarantee complete tumor destruction. For tumors in risk areas (definition shown below), the width of ablative margin was narrowed in the intervals between tumor and adjacent tissues to reach a balance between the need of an ablative margin and the avoidance of heat injury to adjacent tissues.

Ablation strategy (Single/multiple electrode, the total number of ablations needed) were discussed at an interdisciplinary meeting prior to each MWA procedure and were dependent mainly on tumor characteristics and patient general conditions.

1. To treat the majority of tumors within 3 cm in diameter, single ablation plus needle-tract ablation with one electrode was usually sufficient, but for those highly irregular ones, multiple ablations were applied so as to guarantee treatment efficacy.
2. For tumors ranging 3–5 cm in diameter, the strategy of multiple overlapping and needle-tract ablations with one electrode were harnessed. The electrode was inserted until the distal margin of the lesion and then was withdrawn every 1.0–1.5 cm to repeat the ablation.
3. For tumors larger than 5 cm, multi-electrode, multi-tract and multiplanar ablation strategy was used in which two electrodes were inserted parallelly (\(\leq 3\) cm interval) through the same intercostal space to ablate tumor and then repeated the processes through the next intercostal space until the entire tumor was ablated. Detailed ablation parameters were shown in Supplementary Table 1.

After ablation, patients were monitored for a couple of hours in a recovery unit and then were sent back to the ward. A complete panel of blood chemistry including liver and renal functions was examined pre- and post-ablation.

### Definition of risk areas and special ablation techniques for tumors located in these areas.

Based on previous literatures\(^{15,16}\), risk areas were defined as tumor locations within 5 mm of diaphragmatic dome, big vessels (first or second branch of the portal vein, the base of hepatic veins, or the inferior vena cava) or cavity viscera. These areas are regarded as risk areas because percutaneous ablation of tumors in these areas may cause heat injuries to adjacent organs and may be less effective due to heat-sink effect of big vessels\(^{15,17}\).

It should be noted that in our study, patients with tumors of the following characteristics had already been excluded because what they received were laparoscopy-assisted or intraoperative MWA: tumors protruding from liver surface, contacting or adhering to diaphragm or abdominal viscera.

For tumors in risk areas, specific ablation technique and parameters were used. Optional routes of electrode insertion were carefully considered on ultrasound scrutiny and a route with the least possibility of injuring adjacent tissues or vessels was selected. For tumors adjacent to large vessels, the ablation power was set at relatively low level (for example, 80w) to prevent vessel injury whereas the ablation time (Supplementary Table 1) was elongated to improve technique effectiveness for compensation. For tumors near diaphragmatic dome or cavity viscera (such as gastrointestinal tract and gallbladder), multi-angle ablation strategy with relative low power (80w, for example) and shortened ablation time were harnessed to prevent possible heat injuries to these tissues. For patients \((n = 2)\) with tumors too close to the diaphragm, artificial pleural effusion with 5% glucose was used to separate the lung. Similarly, for patients \((n = 3)\) with tumors too close to the gastrointestinal tract, artificial ascites (5% glucose, 250–3000 mL) was used to separate gastrointestinal tract to prevent heat injury (Supplementary Table 1).

### Technique effectiveness and procedure-related complications.

Contrast-enhanced computed tomography (CT) or magnetic resonance (MR) was performed one month after MWA. The ablation was considered complete if the ablation zone completely covered the tumor and if there was no irregular enhancement at the treatment margin, which was recorded as CA11\(^{14}\) (complete ablation at first MWA) and regarded as primary technique effectiveness. Otherwise, an additional session of MWA was performed and the patients were reevaluated.
one month later. If CA was achieved by this time, it was recorded as CA2nd and regarded as secondary technique effectiveness. Otherwise, the treatment was defined as incomplete ablation (IA2nd) and technically failing.

According to the recommendations by the International Working Group on Image-Guided Tumor Ablation18, major procedure-related complications referred to those that lead to substantial morbidity and disability; increase the level of care, or result in hospital admission or substantially lengthens the hospital stay. All other complications were defined as minor. For patients of CA2nd or IA2nd, the complications following the initial and the second sessions of MWA were all recorded for subsequent analysis.

**Patient follow-up and definitions of terminology.** Contrast-enhanced CT or MRI and blood chemistry was performed one month after MWA, every 3 months for the first year, and every 4–6 months thereafter.

Tumor progression and recurrence were defined according to recommendations by the International Working Group on Image-Guided Tumor Ablation18. In patients with primary or secondary technique effectiveness (CA1st or CA2nd), local tumor progression (LTP) was defined as the reappearance of enhancement within or along the margin of the ablation zone on follow-up imagines. Intrahepatic distant recurrence (IDR) was defined as the occurrence of HCC within the liver at locations not contacting the ablation zone. Extrahepatic recurrence (ER) was defined as metastases outside the liver.

Recurrence-free survival (RFS) was calculated from the day of initial MWA to the day of either the earliest event (LTP, IDR, ER or death) or last follow-up without an event. Overall survival (OS) was calculated from the day of initial MWA to the day of death (confirmed by medical records or by family members) or last follow-up.

**Treatment strategy after tumor progression/recurrence.** Treatment strategies after tumor recurrence for patients of CA1st or CA2nd included: liver transplantation in 4 patients, hepatic resection in 4 patients, TACE in 86 patients, TACE plus sorafinib in 4 patients, MWA in 20 patients, RFA in 32 patients, and Chinese traditional medicine in 7 patients. Detailed treatment strategies after tumor progression/recurrence were shown in Supplementary Figure 1.

**Statistical Analysis.** Chi-square test or Fisher’s exact test were used to analyze the correlations between tumor characteristics and technique effectiveness, as well as correlations between tumor characteristics and incidence of complications. Among patients with difference were analyzed with. Median OS (mOS) and median RFS (mRFS) were calculated using the Kaplan-Meier method and compared by the log-rank test. Variables with p values < 0.15 on univariate analyses were included in multivariate analysis (Cox proportional hazards model; Backward selection). All statistical analyses were conducted using SPSS 22.0 (SPSS 22.0 for Windows, SPSS, Chicago, Illinois, USA). p < 0.05 was considered as statistically significant.

**Results**

**Patients’ baseline characteristics.** According to the patient inclusion and exclusion criteria, a total of 221 patients were included in this study finally (Fig. 1), of which 115 died by the last follow-up (Jan 31, 2016). The median follow-up was 41.0 months (ranging from 25.0 to 63.5 months). A total of 21 items of pre-ablation number and location have no significant impact on technique effectiveness. The results showed that patients with tumor size ≤ 5 cm are more likely to suffer from IA2nd and less likely to gain CA1st compared with those with tumor size > 5 cm in size (Table 2). However, tumor number and location have no significant impact on technique effectiveness.

Of the 209 patients with primary or secondary technique effectiveness (CA1st or CA2nd), 170 had suffered from tumor progress or recurrence by the last follow-up, of which 33 were LTP, 120 were IDR, and the other 17 were ER. The median RFS (mRFS) and median OS (mOS) of the total cohort was 14.0 months (95% CI: 9.254–18.746) and 41.0 months (95% CI: 33.741–48.259), respectively. The 1- and 2-year RFS rates were 35.9% (90.95%), CA2nd in 8 (3.62%) whereas the other 12 (5.43%) suffered from technique failure (remaining incomplete ablation [IA2nd] after two sessions of MWA). No patients died within 30 days of MWA. Chi-square test or Fisher’s exact test were performed to investigate whether tumor characteristics (size, number and location) can impact technique effectiveness. The results showed that patients with tumor size > 5 cm are more likely to suffer from IA2nd and less likely to gain CA1st compared with those with tumor size ≤ 5 cm in size (Table 2).

**Technique effectiveness and long term outcomes.** Of these 221 patients, CA1st was gained in 201 (90.95%), CA2nd in 8 (3.62%) whereas the other 12 (5.43%) suffered from technique failure (remaining incomplete ablation [IA2nd] after two sessions of MWA). No patients died within 30 days of MWA. Chi-square test or Fisher’s exact test were performed to investigate whether tumor characteristics (size, number and location) can impact technique effectiveness. The results showed that patients with tumor size > 5 cm are more likely to suffer from IA2nd and less likely to gain CA1st compared with those with tumor size ≤ 5 cm in size (Table 2). However, tumor number and location have no significant impact on technique effectiveness.

On univariate analyses, 6 variables were significant prognosticators of OS: tumor number, tumor size, AFP, GGT, technique effectiveness and type of recurrence (Table 3). Compared with AFP > 400 ng/ml, AFP ≤ 20 ng/ml (hazards ratio [HR], 0.532; 95% CI, 0.338–0.837; p = 0.006) and AFP 20–400 ng/ml (HR, 0.579; 95% CI, 0.346–0.971; p = 0.038) were significant favorable prognosticators of OS (Table 3). Compared with GGT > 50U/L, GGT ≤ 50 (HR, 0.656; 95% CI, 0.434–0.990; p = 0.045) was significant favorable prognosticators of RFS (Table 3).

**Prognostic factors of recurrence-free survival (RFS).** Correlations between RFS and 20 dichotomized variables were tested by univariate analyses (Table S2), the results of which showed that the levels of alpha fetoprotein (AFP) and gamma-glutamyl transpeptidase (GGT) significantly correlated with RFS (Fig. 2, Table S2).

On multivariate analyses, levels of AFP and GGT remain significant prognosticators of RFS (Table 3). Compared with AFP > 400 ng/ml, AFP ≤ 20 ng/ml (hazards ratio [HR], 0.532; 95% CI, 0.338–0.837; p = 0.006) and AFP 20–400 ng/ml (HR, 0.579; 95% CI, 0.346–0.971; p = 0.038) were significant favorable prognosticators of RFS (Table 3). Compared with GGT > 50U/L, GGT ≤ 50 (HR, 0.656; 95% CI, 0.434–0.990; p = 0.045) was significant favorable prognosticators of RFS (Table 3).

**Prognostic factors of overall survival (OS).** On univariate analyses, 5 variables significantly correlated with OS: tumor size, AFP, GGT, technique effectiveness and type of recurrence (Fig. 3, Table S2). For example, the mOS of patients with CA1st, CA2nd and IA2nd were 43 months (95% CI: 34.526–62.834), 14 months (95% CI: 0.000–30.631) and 12 months (95% CI: 4.079–19.921) respectively (p < 0.001) (Fig. 3).

On multivariate analysis, 6 variables were significant prognosticators of OS: tumor number, tumor size, AFP, GGT and type of recurrence (Table 4, Fig. 3). Compared with one tumor lesion, two lesions were significant unfavorable prognosticators of OS (HR, 3.148; 95% CI, 1.747–5.672; p < 0.001), three lesions also showed an
unfavorable trend albeit without statistical significance (HR, 2.116; 95% CI, 0.967–4.633; \( p = 0.061 \)). Compared with AFP \( > 400 \text{ ng/ml} \), AFP \( \leq 20 \text{ ng/ml} \) (HR, 0.530; 95% CI, 0.323–0.870; \( p = 0.012 \)) and AFP 20–400 ng/ml (HR, 0.565; 95% CI, 0.372–0.977; \( p = 0.041 \)) were significant favorable prognosticators (Table 4). Compared with tumor size \( > 5 \text{ cm} \), tumor size \( \leq 3/3–5/5 \) cm (HR, 0.106; 95% CI, 0.044–0.255; \( p < 0.001 \)) and 3–5 cm (HR, 0.276; 95% CI, 0.142–0.536; \( p < 0.001 \)) were significant favorable prognosticators. Compared with LTP, IDR (HR, 0.150; 95% CI, 0.174–0.303; \( p < 0.001 \)) was significant favorable prognosticators whereas ER (HR, 6.249; 95% CI, 1.692–23.072; \( p = 0.006 \)) was significant unfavorable prognosticators. Besides, GGT \( \leq 50 \text{ U/L} \) (HR, 0.32; 95% CI, 0.193–0.572; \( p < 0.001 \)) and ALK \( \leq 110 \text{ U/L} \) (HR, 0.593; 95% CI, 0.400–0.880; \( p = 0.057 \)) were significant favorable prognosticators of OS relative to GGT > 50 U/L and ALK > 110 U/L, respectively (Table 4, Fig. 3).

### Complications.

A total of 22 (10.4%) complications were observed during follow-up, of which 8 (3.8%) were major complications (Table 5). All these complications subsided naturally or after medication. There was no procedure-related death. Chi-square test or Fisher’s exact test showed that tumor size \( \leq 3/3–5/5 \) cm, tumor number (1/2/3) and tumor location (risk/non-risk areas) do not significantly influence complication rates (Supplementary Table 3).
Discussion

To date, only a few studies\textsuperscript{15,17,19,20} have investigated the prognosticators of RFS and OS in patients with HCC who received MWA as an initial treatment, and the majority of these studies suffered from some shortcomings such as small cohort size\textsuperscript{15,19–22}, small number of variables to be analyzed\textsuperscript{21,22}, restriction to tumors in a special range of sizes\textsuperscript{15,20–22} or in special areas\textsuperscript{17}. Our study, on the contrary, included 221 treatment-naïve patients who received percutaneous MWA as an initial therapy and recorded up to 22 variables for survival analysis. In our study, tumor size ranged from 1 cm to 10 cm, tumor number ranged from 1 to 3, and tumor locations included both risk and non-risk areas. To the best of our knowledge, ours is the first to comprehensively analyze prognosticators of RFS and OS in HCC patients receiving MWA as an initial treatment.

Our results showed that lower levels of AFP and GGT were significant favorable predictors of RFS on both uni- and multivariate analyses (Table 3, Supplementary Table 2). As for OS, univariate analyses identified 5 significant prognosticators: tumor size, levels of AFP and GGT, technique effectiveness and types of recurrence (Supplementary Table 2). On multivariate analysis, independent significant prognosticators of OS were: tumor number, tumor size, AFP, GGT and types of recurrence (Table 4).

There are several interesting findings in our results that may help to guide patient selection and clinical practice of MWA for HCC. First, although technique effectiveness is not an independent significant prognosticator of OS on multivariate analysis (Table 4), it significantly influence OS on univariate analysis in that the mOS of patients with CR1\textsuperscript{1st}, CR2\textsuperscript{2nd} and IA2\textsuperscript{2nd} were 43.0 months (95% CI: 34.5–51.5), 14.0 months (95% CI: 0.0–31.6) and 12.0 months (95% CI: 4.1–19.9), respectively (\(p < 0.001\)) (Supplementary Table 2). This is in line with the results of previous studies on other percutaneous ablation techniques that highlighted the importance of initial complete response in survival prediction\textsuperscript{23}. In some studies\textsuperscript{13,24}, however, CA1\textsuperscript{1st} and CA2\textsuperscript{2nd} were both regarded as ablation success whereas IA2\textsuperscript{2nd} was regarded as ablation failure. Our study suggests the necessity of future studies to investigate whether it is more rational to regard CA1\textsuperscript{1st} as ablation success whereas CA2\textsuperscript{2nd} and IA2\textsuperscript{2nd} as ablation failure.

**Table 3.** Multivariate analyses of prognostic factors of recurrence-free survival. Variables with \(p\) values of <0.25 on univariate analyses were included in multivariate analysis (Cox proportional hazards model). AFP: alpha fetal protein; ALT: alanine transaminase; GGT: gamma-glutamyl transpeptidase; ALK: alkaline phosphatase; TBil: total bilirubin; *Tumor number 1 vs 3. #Tumor number 2 vs 3; They represent the same meaning in other polytomous variables.

**Table 4.** Kaplan-Meier curves of patients’ recurrence-free survival by levels of AFP (A) and GGT (B). AFP: alpha fetoprotein; GGT: gamma-glutamyl transpeptidase.
Second, our study revealed that MW A can provide complete tumor ablation in the majority of tumors >5 cm (81.8% for CA1st and 3.6% for CA2nd). Although tumors >5 cm are not recommended for local ablative therapies in mainstream guidelines, there were 55 patients with tumors >5 cm in our study who received MWA rather than TACE as an initial treatment because these tumors could be clearly delineated under ultrasound and had a high likelihood to be completely ablated by MWA as assessed by our HCC expert team. Our results showed that CA1st was gained in 81.8% of these patients, much higher than the reported initial complete response rate (36.8%, 71/193) of HCC patients receiving repetitive TACE. Therefore, our study overturned a previous assumption that MWA is unable to provide CA for the majority of patients with large HCC. This advance might be attributable to the improvements in MWA equipment and the special techniques we used (multi-electrode, multi-tract and multiplanar ablation strategy) to enable the enlarged ablation range for large HCC. Future perspective studies are needed to compare the long-time efficacy of MWA with those of other therapeutic modalities such as resection or TACE to determine the optimal treatment modalities for this patient population.

Third, tumors located in risk areas (defined exactly as in our study) did not significantly affect RFS, OS and complication rates and should not be regarded as a contraindication to MWA treatment. Controversies long exist regarding the influence of “risk areas” on treatment efficacy of MWA. A previous study, for example, reported that risk areas (using similar definition with ours but not excluding tumors contacting or adhering to neighboring tissues) were independent predictors of tumor recurrence after MWA in a small cohort of HCC patients (n = 45), whereas another study reported that tumors located within 5 mm of large vessels did not affect patients’ RFS and OS following MWA in a large patient cohort (n = 452). This discrepancy may root in different ablation techniques, different sizes of study cohort, and different definitions of “risk areas.” Interestingly, the results of our study are resonant with a previous study on RFA of HCC in which tumors located in risk areas (using similar definition with ours but not excluding tumors contacting or adhering to neighboring tissues) did not significantly affect LTP and rates of early complications.

Forth, the mOS of patients with LTP (21.0 months; 95% CI: 15.120–26.880) was significantly shorter than that of patients with IDR (51.0 months; 95% CI: 39.403–62.597) (p < 0.001), lending support to a previous assumption that LTP might be another form of incomplete ablation, in which the residual tumor cells get into a dormant state following ablation and afterwards become the source of recurrence.

However, our study also suffers from some limitations. First, due to its retrospective nature, there were inevitable selection biases in study population. Second, as the vast majority (181/221) of patients in our study had HBV infection, the scenario of antiviral treatments they received may also impact both RFS and OS and thus should be taken into analyses. However, these data are missing in our study.

In conclusion, our study analyzed long-term outcomes and prognosticators of RFS and OS in HCC patients receiving MWA as an initial treatment. Our results suggest that MWA provides high technique effectiveness rate...
and is well tolerated in patients with HCC. We identified levels of AFP and GGT as independent prognosticators of RFS and identified tumor number, tumor size, AFP, GGT and recurrence type as independent prognosticators of OS, which may guide patient selection and prognosis prediction and hold the potential of changing clinic practice of MWA for HCC. These results need to be validated in larger patient cohorts, and prognostic nomograms need to be developed in the future to provide reliable and convenient systems for the prediction of RFS and OS in HCC patients receiving MWA.

### References

1. Jemal, A. *et al.* Global cancer statistics. *CA Cancer J Clin* **61**, 69–90 (2011).
2. Torre, L. A. *et al.* Global cancer statistics, 2012. *CA Cancer J Clin* **65**, 87–108 (2015).
3. Qi, X., Wang, D., Su, C., Li, H. & Guo, X. Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: A systematic review and meta-analysis. *Oncotarget* **6**(21), 18715–18733 (2015).
4. Zhu, Q. *et al.* Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. *Oncotarget* **6**(6), 4440–4450 (2015).
5. Bruix, J., Sherman, M. & American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology* **53**(3), 1020–1022 (2011).
6. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* **56**(4), 908–943 (2012).
7. Head, H. W. & Dodd, G. D. 3rd. Thermal ablation for hepatocellular carcinoma. *Gastroenterology* **127**(5 Suppl 1), S167–S178 (2004).

### Table 4. Multivariate analysis of overall survival.

Variables with p values of <0.25 on univariate analyses were included in multivariate analysis (Cox proportional hazards model). AFP: alpha fetal protein; GGT: gamma-glutamyl transpeptidase; ALK: alkaline phosphatase; TBil: total bilirubin; CLIP: Cancer of the Liver Italian Program; BCLC: Barcelona Clinic Liver Cancer; CA1st: complete ablation at first microwave ablation (MWA); CA2nd: incomplete ablation at first MWA but complete ablation at second MWA; IA: remaining incomplete ablation after two sessions of MWA. LTR: local tumor recurrence; IDR: interhepatic distant recurrence; ER: extrahepatic recurrence. *Tumor size ≤3 vs >5 cm; AFP ≤20 vs >400 ng/ml; CA1st vs IA.*

| Clinicopathologic features | HR     | 95% CI    | p value |
|---------------------------|--------|-----------|---------|
| Tumor number              | 1      |           |         |
|                           | 2      | 3.148     | 1.747–5.672 | <0.001* |
|                           | 3      | 2.116     | 0.967–4.633 | 0.061†  |
| Tumor size, cm            | ≤3     | 0.106     | 0.044–0.255 | <0.001* |
|                           | 3–5    | 0.276     | 0.142–0.536 | <0.001* |
|                           | >5     |           |         |
| AFP, ng/ml                | ≤20    | 0.530     | 0.323–0.870 | 0.012*  |
|                           | 20–400 | 0.565     | 0.372–0.977 | 0.041†  |
|                           | >400   |           |         |
| ALK, U/L                  | ≤110   | 0.593     | 0.400–0.880 | 0.057   |
|                           | >110   |           |         |
| GGT, U/L                  | ≤50    | 0.332     | 0.193–0.572 | <0.001  |
|                           | >50    |           |         |
| Ablation effectiveness    | CA1st  | 0.499     | 0.222–0.123 | 0.039   |
|                           | CA2nd  | 0.517     | 0.145–1.840 | 0.308*  |
|                           | IA     |           |         |
| Types of recurrence       | LTP    | 0.150     | 0.174–0.303 | <0.001* |
|                           | IDR    | 0.150     | 0.174–0.303 | <0.001* |
|                           | ER     | 6.249     | 1.692–23.072| 0.006†  |

### Table 5. Post-procedure complications after initial and/or second MWA.

| Complication                 | Number of complications | Number of major complications |
|-----------------------------|-------------------------|-------------------------------|
| Pleural effusion            | 5                       | 1                             |
| Ascites                     | 2                       | 0                             |
| Intraperitoneal hemorrhage  | 2                       | 0                             |
| Hyperbilirubinemia          | 5                       | 2                             |
| Hepatic encephalopathy      | 1                       | 1                             |
| Renal deficiency            | 6                       | 3                             |
| Adrenal crisis              | 1                       | 1                             |
| Total                       | 22 (10.4%)              | 8 (3.8%)                      |
8. Yu, Z. et al. Treatment of osteosarcoma with microwave thermal ablation to induce immunogenic cell death. *Oncotarget* 5(15), 6526–6539 (2014).
9. Andreano, A. & Brace, C. L. A comparison of direct heating during radiofrequency and microwave ablation in *ex vivo* liver. *Cardiovasc Intervent Radiol* 36, 505–511 (2013).
10. Andreano, A., Huang, Y., Meloni, M. F., Lee, F. T. & Brace, C. Microwaves create larger ablations than radiofrequency when controlled for power in *ex vivo* tissue. *Med Phys* 37, 2967–2973 (2010).
11. Chinnaratha, M. A., Chuang, M. A., Fraser, R. J., Woodman, R. J. & Wigg, A. I. Percutaneous thermal ablation for primary hepatocellular carcinoma: A systematic review and meta-analysis. *J Gastroenterol Hepatol* 31(2), 294–301 (2016).
12. Molla, N. et al. The role of interventional radiology in the management of hepatocellular carcinoma. *Curr Oncol* 21(3), e480–e492 (2014).
13. Kudo, M., Chung, H. & Osaki, Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). *J Gastroenterol* 38, 207–215 (2003).
14. Llovet, J. M., Brú, C. & Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis* 19, 329–338 (1999).
15. Zhang, N. N. et al. High-powered microwave ablation of larger hepatocellular carcinoma: evaluation of recurrence rate and factors related to recurrence. *Clin Radiol* 70(11), 1237–1243 (2015).
16. Teratani, T. et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. *Hepatology* 43(5), 1101–1108 (2006).
17. Huang, S. et al. Percutaneous microwave ablation for hepatocellular carcinoma adjacent to large vessels: a long-term follow-up. *Eur J Radiol* 83(3), 552–558 (2014).
18. Goldberg, S. N. et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. *Radiology* 235, 728–739 (2005).
19. Alexander, E. S. et al. Microwave ablation of focal hepatic malignancies regardless of size: A 9-year retrospective study of 64 patients. *Eur J Radiol* 84(6), 1083–1090 (2015).
20. Medhat, E. et al. Value of microwave ablation in treatment of large lesions of hepatocellular carcinoma. *J Dig Dis* 16(8), 456–463 (2015).
21. Sun, A. X. et al. Clinical outcome of medium-sized hepatocellular carcinoma treated with microwave ablation. *World J Gastroenterol* 21(10), 2997–3004 (2015).
22. Liang, P. C., Lai, H. S., Shih, T. T., Wu, C. H. & Huang, K. W. Initial institutional experience of uncooled single-antenna microwave ablation for large hepatocellular carcinoma. *Clin Radiol* 70(5), e35–e40 (2015).
23. Sala, M. et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. *Hepatology* 40(6), 1352–1360 (2004).
24. Peng, Z. W. et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. *J Clin Oncol* 31(4), 426–432 (2013).
25. Kim, B. K. et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. *J Hepatol* 62(6), 1304–1310 (2015).
26. Ogihara, M., Wong, L. L. & Machi, J. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. *HPB: the official journal of the International Hepato Pancreato Biliary Association* 7(3), 214–221 (2005).

Acknowledgements
This work was supported by National Natural Science Foundation of China (81102014) and National Natural Science Foundation of China (81201678).

Author Contributions
B.Z. T.W. and X.-J.L. designed the study. B.Z., T.W. Y.Z., X.-Y.T., P.L. and J.-C.C. collected and analyzed the data. X.-J.L. and X.-Y.Z. wrote the manuscript. L.Z. and B.Z. conducted the statistical analyses. M.D. was responsible for statistical correctness.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Wang, T. et al. Microwave ablation of hepatocellular carcinoma as first-line treatment: long term results and prognostic factors in 221 patients. *Sci. Rep.* 6, 32728; doi: 10.1038/srep32728 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016